AI entity

Insilico Medicine

Company

All 1 tracked stories fall under one category: partnership. Of the tracked stories, 1 of 1 also mention BIO International Convention 2026, the most common co-covered peer. The tracked stories average 2 original sources each. Insilico Medicine appears in 1 tracked AI story from June 23, 2026.

Last mentioned: Jul 15, 2026

RSS updates
Share

Entity pulse

Recent coverage · Insilico Medicine

1 story
8 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Insilico Medicine

All 1 tracked stories fall under one category: partnership. Of the tracked stories, 1 of 1 also mention BIO International Convention 2026, the most common co-covered peer. The tracked stories average 2 original sources each. Insilico Medicine appears in 1 tracked AI story from June 23, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 15 AI stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Insilico Medicine. Shared-story counts are live from our verified record — not editorial picks.

Key Data

ticker
3696
name
Insilico Medicine
price
null
change
null
changePct
null

Timeline

  1. Collaboration Announced at BIO 2026

    Insilico Medicine and SK Biopharmaceuticals announced a research and development collaboration, value up to $2.5 billion, to discover AI‑enabled drug candidates for neuroimmune disorders of the CNS.

Stories mentioning Insilico Medicine 1

Partnerships Strongly positive

$2.5B Partnership: Generative AI Platform Captures Largest CNS Drug Deal

Insilico Medicine's Pharma.AI generative AI platform landed a record $2.5B collaboration with SK Biopharmaceuticals to design and optimize therapeutics for neuroimmune disorders. The deal, announced at BIO 2026, represents the largest validation of an end‑to‑end AI drug discovery engine in the CNS space, proving that generative modeling can transcend oncology and infuse new life into neurology pipelines.

2 sources

Source: aijourn.com · news-medical.net

Insilico Medicine is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.